Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of inhaled ALX-0171 in infants and young children hospitalized with RSV lower respiratory tract infection
2016-001651-49Phase 2Completed
- Sponsor
- Ablynx
- Start
- Aug 2016
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gontivimab in respiratory syncytial virus disease (RSV) (4 arms), sponsored by Ablynx. Primary endpoint: Time to viral load below assay quantification limit. Started Aug 2016; status: completed.
02
Drugs
gontivimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2016-001651-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001651-49.